Related Experiment Video
Updated: May 12, 2026
14:57
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Genetic Polymorphism of GSTM1, GSTT1, GSTP1 Genes and Breast Cancer Risk in Rural Maharashtra: Insights from a Case-
Kailas D Datkhile1, Suresh J Bhosale2, Rashmi A Gudur3
1Department of Molecular Biology & Genetics, Krishna Institute of Allied Sciences, Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist- Satara, Pin-415 539, (Maharashtra) India.
Asian Pacific Journal of Cancer Prevention : APJCP
|March 29, 2025
Summary
Glutathione S-transferase T1 (GSTT1) null genotypes increase breast cancer risk by 2.45-fold in rural Maharashtra women. Conversely, GSTP1 heterozygous variants are linked to decreased breast cancer susceptibility.
Area of Science:
- Genetics
- Oncology
- Molecular Epidemiology
Background:
- Breast cancer (BC) is a complex disease influenced by genetic factors.
- Previous studies on glutathione S-transferase (GST) gene polymorphisms and BC risk show global discrepancies.
- This study investigates GST gene isoform polymorphisms and BC susceptibility in rural Maharashtra.
Purpose of the Study:
- To assess the association between GSTM1, GSTT1, and GSTP1 gene polymorphisms and breast cancer risk.
- To evaluate the correlation of these genetic variations with BC susceptibility in a rural Indian population.
Main Methods:
- Polymerase chain reaction (PCR) was used to study GSTM1 and GSTT1 polymorphisms in 400 BC cases and 400 controls.
- PCR-restriction fragment length polymorphism (PCR-RFLP) analyzed GSTP1 Ile/Val and Ala/Val variants.
- Logistic regression and Odds Ratios (OR) with 95% confidence intervals (CI) determined the association with BC risk.
Main Results:
- GSTT1 null genotypes (-/-) were significantly associated with increased BC risk (OR = 2.45; 95% CI = 1.73-3.48).
- GSTP1 heterozygous Ala/Val genotype showed a significant association with decreased BC risk (OR = 0.26; 95% CI = 0.18-0.35).
Conclusions:
- GSTT1 null genotype is a significant risk factor for breast cancer in rural Maharashtra women.
- GSTP1 heterozygous variant genotype demonstrates a protective effect against breast cancer in this population.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...